High-dose anakinra improved the survival rate at 21 days compared to SOC-treated patients (90% vs. 56%; HR 0.20, 95% CI 0.04–0.63, p=0.009).Most common AEs in high-dose anakinra-treated patients were bacteremia (14%) and increase in liver enzymes (10%).Low-dose anakinra-treated patients did not show any effect neither on CRP levels nor on clinical improvement after 7 days and was withdrawn. The gene discussed is CRP; the disease is bacterial infectious disease with sepsis.